Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Cenexi, a French contract development and manufacturing organization (CDMO) specializing in the formulation, analytical development, and manufacture of complex molecule drugs, have formed a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the EU. The initial step of the collaboration includes the execution of a Master ...